HostSeq : A Canadian Whole Genome Sequencing and Clinical Data Resource
Author:
Yoo S, Garg EORCID, Elliott LTORCID, Hung RJORCID, Halevy AR, Brooks JD, Bull SB, Gagnon F, Greenwood CMTORCID, Lawless JF, Paterson ADORCID, Sun LORCID, Zawati MH, Lerner-Ellis JORCID, Abraham RJS, Birol IORCID, Bourque GORCID, Garant J-M, Gosselin C, Li J, Whitney J, Thiruvahindrapuram BORCID, Herbrick J-A, Lorenti M, Reuter MS, Adeoye NO, Liu S, Allen UORCID, Bernier FP, Biggs CM, Cheung AMORCID, Cowan JORCID, Herridge MORCID, Maslove DMORCID, Modi BP, Mooser V, Morris SKORCID, Ostrowski MORCID, Parekh RSORCID, Pfeffer GORCID, Suchowersky O, Taher J, Upton JORCID, Warren RL, Yeung RSMORCID, Aziz N, Turvey SEORCID, Knoppers BMORCID, Lathrop M, Jones SJM, Scherer SWORCID, Strug LJORCID
Abstract
ABSTRACTHostSeq was launched in April 2020 as a national initiative to integrate whole genome sequencing data from 10,000 Canadians infected with SARS-CoV-2 with clinical information related to their disease experience. The mandate of HostSeq is to support the Canadian and international research communities in their efforts to understand the risk factors for disease and associated health outcomes and support the development of interventions such as vaccines and therapeutics. HostSeq is a collaboration among 13 independent epidemiological studies of SARS-CoV-2 across five provinces in Canada. Aggregated data collected by HostSeq are made available to the public through two data portals: a phenotype portal showing summaries of major variables and their distributions, and a variant search portal enabling queries in a genomic region. Individual-level data is available to the global research community for health research through a Data Access Agreement and Data Access Compliance Office approval. Here we provide an overview of the collective project design along with summary level information for HostSeq. We highlight several statistical considerations for researchers using the HostSeq platform regarding data aggregation, sampling mechanism, covariate adjustment, and X chromosome analysis. In addition to serving as a rich data source, the diversity of study designs, sample sizes, and research objectives among the participating studies provides unique opportunities for the research community.
Publisher
Cold Spring Harbor Laboratory
Reference65 articles.
1. Government of Canada. COVID-19 signs, symptoms and severity of disease: A clinician guide. 2021 [Accessed Summer 2022]. Available from: https://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirus-infection/guidance-documents/signs-symptoms-severity.html 2. Statistical power in COVID-19 case-control host genomic study design;Genome Med,2020 3. CCR5Δ32 mutation and HIV infection: basis for curative HIV therapy 4. Genetic Susceptibility to Human Norovirus Infection: An Update 5. Role of interleukin 28-B in the spontaneous and treatment-related clearance of HCV infection in patients with chronic HBV/HCV dual infection;Eur J Clin Microbiol Infect Dis,2014
|
|